Cardiff Oncology, Inc.
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
CRDF | NDAQ
Overview
Corporate Details
- ISIN(s):
- US14147L1089
- LEI:
- Country:
- United States of America
- Address:
- 11055 FLINTKOTE AVENUE, 92121 SAN DIEGO
- Website:
- https://cardiffoncology.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for various cancers. The company's approach centers on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead asset, onvansertib, is a PLK1 inhibitor being evaluated in clinical programs in combination with standard-of-care (SoC) therapeutics. Cardiff's development strategy is designed to target tumor vulnerabilities, aiming to overcome treatment resistance and deliver superior clinical benefits for patients, particularly in indications with a significant need for new treatment options.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Cardiff Oncology, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cardiff Oncology, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cardiff Oncology, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
